References
1. Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm
intervention in the early stages of COVID-19 pneumonia. Cytokine Growth
Factor Rev. 2020;53:38‑42.
2. Gracia-Ramos AE, Saavedra-Salinas MÁ. Can the SARS-CoV-2 infection
trigger systemic lupus erythematosus? A case-based review. Rheumatol
Int. 2021;1‑11.
3. Joo YB, Lim Y-H, Kim K-J, Park K-S, Park Y-J. Respiratory viral
infections and the risk of rheumatoid arthritis. Arthritis Res Ther
[Internet]. 2019;21.
4. Gasparotto M, Framba V, Piovella C, Doria A, Iaccarino L.
Post-COVID-19 arthritis: a case report and literature review. Clin
Rheumatol. 2021;1‑6.
5. Cooper GS, Dooley MA, Treadwell EL, Clair EWS, Gilkeson GS. Risk
factors for development of systemic lupus erythematosus: Allergies,
infections, and family history. J Clin Epidemiol. 2002;55(10):982‑9.
6. Anaya J-M, Monsalve DM, Rojas M, Rodríguez Y, Montoya-García N,
Mancera-Navarro LM, et al. Latent rheumatic, thyroid and phospholipid
autoimmunity in hospitalized patients with COVID-19. J Transl Autoimmun.
2021;4:100091.
7. Fujii H, Tsuji T, Yuba T, Tanaka S, Suga Y, Matsuyama A, et al. High
levels of anti-SSA/Ro antibodies in COVID-19 patients with severe
respiratory failure: a case-based review : High levels of anti-SSA/Ro
antibodies in COVID-19. Clin Rheumatol. 2020;39(11):3171‑5.
8. Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D,
et al. High prevalence of antinuclear antibodies and lupus anticoagulant
in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol.
2020;39(7):2095‑7.
9. Dotan A, Shoenfeld Y. [COVID-19 AND AUTOIMMUNE DISEASES].
Harefuah. 2021;160(2):62‑7.